Loading clinical trials...
Loading clinical trials...
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
Conditions
Interventions
GTB-3550 TriKE® Phase I
GTB-3550 TriKE® Phase II
Locations
2
United States
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
University of Wisconsin Clinical Science Center
Madison, Wisconsin, United States
Start Date
January 1, 2020
Primary Completion Date
August 2, 2021
Completion Date
September 29, 2021
Last Updated
November 10, 2022
NCT06656494
NCT06859424
NCT07347171
NCT07254312
NCT02143830
NCT07142473
Lead Sponsor
GT Biopharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions